Tag: KDC-MN-080

  • Tesamorelin

    Stabilized GHRH analog

    A trans-3-hexenoic acid stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy.

    Abstract

    Tesamorelin (Egrifta; CAS 901758-09-6; molecular weight 5135.79) is a stabilized analog of human GHRH developed by Theratechnologies (Canada) and approved by the FDA in 2010 for HIV-associated lipodystrophy. The structural modification is the addition of a trans-3-hexenoic acid group at the N-terminus, which substantially extends plasma half-life relative to native GHRH or sermorelin. The compound stimulates physiological GH release with restored visceral adipose tissue reduction in HIV patients on antiretroviral therapy. Pharmacokinetics: plasma half-life approximately 26 minutes (versus 11 to 12 minutes for sermorelin); subcutaneous administration.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.